About Neuronal acetylcholine receptor subunit alpha-9
Neuronal acetylcholine receptor subunit alpha-9 (CHRNA9) is a protein
from Homo sapiens identified by UniProt accession
Q9UGM1, 479 residues long.
MolForge cross-references it against 0 known binders and
68 disease associations.
Target properties
| Protein name | Neuronal acetylcholine receptor subunit alpha-9 |
| UniProt accession | Q9UGM1 |
| Gene | CHRNA9 |
| Organism | Homo sapiens |
| Length | 479 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (68)
Diseases linked to this target (Open Targets).
- Tinnitus · score 0.40
- hypothyroidism · score 0.36
- lymphocyte count · score 0.33
- Graves disease · score 0.32
- Hashimoto's thyroiditis · score 0.30
- Thyroid preparation use measurement · score 0.29
- Alzheimer disease · score 0.26
- thyroid gland adenocarcinoma · score 0.25
- hematocrit · score 0.24
- DNA methylation · score 0.24
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9UGM1-F1 | alphafold | PREDICTED | 80.93 | — |
Amino-acid sequence (479 residues)
MNWSHSCISF CWIYFAASRL RAAETADGKY AQKLFNDLFE DYSNALRPVE DTDKVLNVTL QITLSQIKDM DERNQILTAY LWIRQIWHDA YLTWDRDQYD GLDSIRIPSD LVWRPDIVLY NKADDESSEP VNTNVVLRYD GLITWDAPAI TKSSCVVDVT YFPFDNQQCN LTFGSWTYNG NQVDIFNALD SGDLSDFIED VEWEVHGMPA VKNVISYGCC SEPYPDVTFT LLLKRRSSFY IVNLLIPCVL ISFLAPLSFY LPAASGEKVS LGVTILLAMT VFQLMVAEIM PASENVPLIG KYYIATMALI TASTALTIMV MNIHFCGAEA RPVPHWARVV ILKYMSRVLF VYDVGESCLS PHHSRERDHL TKVYSKLPES NLKAARNKDL SRKKDMNKRL KNDLGCQGKN PQEAESYCAQ YKVLTRNIEY IAKCLKDHKA TNSKGSEWKK VAKVIDRFFM WIFFIMVFVM TILIIARAD
Explore Neuronal acetylcholine receptor subunit alpha-9 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets